Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Contemporary Clinical Trials Communications|May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trialMuhammad Ali, Simon Wood, David Pryor, et al.
European Urology|February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer PatientsAndrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Prostate Cancer and Prostatic Diseases|August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and riskArun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Ebiomedicine|August 7, 2023
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotypeHeidi Fettke, Chao Dai, Edmond M Kwan, et al.
BJU International|November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancerRichard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case SeriesMichal Eifer, Duncan E K Sutherland, Isaac Goncalves, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
British Journal of Cancer|November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomyYiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Contemporary Clinical Trials Communications|May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trialMuhammad Ali, Simon Wood, David Pryor, et al.
European Urology|February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer PatientsAndrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Prostate Cancer and Prostatic Diseases|August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and riskArun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Ebiomedicine|August 7, 2023
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotypeHeidi Fettke, Chao Dai, Edmond M Kwan, et al.
BJU International|November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancerRichard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case SeriesMichal Eifer, Duncan E K Sutherland, Isaac Goncalves, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
British Journal of Cancer|November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomyYiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Pageof 14